StockData

Natures Sunshine Products vs OPKO Health

NATR and OPK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NATR and OPK compare

OPKO Health is the larger company, worth 6.5 times as much as Natures Sunshine Products ($1.2B against $186M).

Natures Sunshine Products grew revenue faster over the last twelve months (6.8% versus −11.5% for OPKO Health).

Natures Sunshine Products keeps more of each dollar of sales as profit, with a net margin of 3.7% compared with −12.4% at OPKO Health.

Natures Sunshine Products scores higher on the StockData Score (16 against 9 for OPKO Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNATROPK
Size and price
Market cap$186M$1.2B
Share price$10.56$1.62
Change, 1 year−49.1%26.6%
Change, 5 years−38.2%−60.8%
Beta (5Y)0.180.36
Employees8062,275
StockData Score
Total score16 (better)9
Valuation score6 (better)1
Growth score2 (better)1
Performance score23 (better)
Health score6 (better)4
Dividend score00
Valuation
P/E10.5×–
P/S0.4× (better)2.1×
P/B–1.0×
EV/EBITDA2.4× (better)22.0×
P/FCF10.3×–
FCF yield9.7% (better)−11.1%
Fair value$24.66$1.55
Margin of safety57.2% (better)−4.8%
Growth
Revenue growth (TTM)6.8% (better)−11.5%
Revenue growth, 5Y average4.5% (better)−15.8%
Net income growth (TTM)28.3%–
EPS growth (TTM)36.5%–
EPS growth, 5Y average−0.19%–
Profitability
Gross margin73.2% (better)40.8%
Operating margin6.0% (better)−8.2%
Net margin3.7% (better)−12.4%
FCF margin3.7% (better)−22.8%
Return on equity–−5.9%
Return on invested capital–−4.0%
Financial health
Debt / equity–0.00
Net debt / EBITDA–−7.19
Interest coverage208×–
Current ratio2.603.35 (better)
Altman Z-score4.47 (better)−0.21
Piotroski F-score8 (better)4
Dividends and buybacks
Buyback yield3.5%3.9% (better)
Shareholder yield3.5%3.9% (better)
Ownership
Held by institutions90.1%27.2%
Held by insiders25.5%43.6%
Insider net buying, 12 months$3.7M (better)−$13.2K
Short interest, % of float8.1%7.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.